Royalty Pharma declares a $0.22 dividend per share for Q1 2025, a 5% increase from the previous quarter.
Quiver AI Summary
Royalty Pharma plc has announced a quarterly dividend of $0.22 per Class A ordinary share for the first quarter of 2025, marking a 5% increase from the previous quarter. The dividend will be paid on March 10, 2025, to shareholders recorded by February 21, 2025. Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation in the industry. It collaborates with a range of organizations to support late-stage clinical trials and new product launches, acquiring royalties from innovators. The company’s portfolio includes royalties on over 35 products, such as Vertex’s Trikafta and GSK’s Trelegy, along with several development-stage candidates.
Potential Positives
- The company announced a 5% increase in its quarterly dividend, indicating strong financial performance and commitment to returning value to shareholders.
- The declared dividend reflects a stable and growing income potential for investors, which may attract more institutional and retail investors.
- The dividend will be paid to a broad shareholder base, reinforcing the company's reputation and reliability in shareholder returns.
- Royalty Pharma's diverse portfolio of royalties on over 35 commercial products positions it well for future revenue generation and growth.
Potential Negatives
- None
FAQ
What is the new dividend declared by Royalty Pharma for Q1 2025?
Royalty Pharma declared a dividend of $0.22 per Class A ordinary share for the first quarter of 2025.
When will the dividend be paid to shareholders?
The dividend will be paid on March 10, 2025, to shareholders of record as of February 21, 2025.
How much has the quarterly dividend increased compared to the previous quarter?
The quarterly dividend has increased by 5% over the previous quarter’s dividend.
What is Royalty Pharma's primary business focus?
Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation in the biopharmaceutical industry.
How many commercial products does Royalty Pharma's portfolio include?
Royalty Pharma's current portfolio includes royalties on more than 35 commercial products.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPRX Hedge Fund Activity
We have seen 205 institutional investors add shares of $RPRX stock to their portfolio, and 159 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 6,449,863 shares (-83.3%) from their portfolio in Q3 2024
- UNISPHERE ESTABLISHMENT removed 5,000,000 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 3,055,283 shares (-6.9%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 1,991,225 shares (+84.7%) to their portfolio in Q3 2024
- AMUNDI added 1,627,093 shares (+78.8%) to their portfolio in Q3 2024
- DEUTSCHE BANK AG\ added 1,362,476 shares (+139.1%) to their portfolio in Q3 2024
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 1,103,341 shares (+58.1%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.
The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit
www.royaltypharma.com
.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
